Floatz logo

Surufatinib

Fallopian Tube Carcinosarcoma

Sun Yat-sen UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Fallopian Tube Carcinosarcoma cohort.

Asset / SponsorPhaseRating
Multi-Epitope Folate Receptor Alpha-Loaded Dendritic Cell Vaccine
Mayo Clinic
Phase 2B
Pembrolizumab
Mayo Clinic
Phase 2B
Inno-206
National Cancer Institute (NCI)
Phase 2B
ADSORBED PURIFIED PERTUSSIS VACCINE
Mayo Clinic
Phase 2CCC
Hycamtin
Mayo Clinic
Phase 2CCC

View all 20 →

Same molecule, other indications

Surufatinib is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
65 / 100
View asset →
neuroendocrine neoplasmDormant
BB
Indicative ·
64 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →